Volume Alert - MACK 8.50 Merrimack Pharmaceuticals Inc $MACK Hit a high today of 8.64 Closing the day 10:30 at 8.50 -0.05 -0.58% With a day low of 8.32 and a total volume of 958,820.
MACK Recent Posts: http://investorshangout.com/Merrimack-Pharmac...ACK-90045/
MACK Merrimack Pharmaceuticals Inc Recent Headline News
Biothera Names Carey Anderson VP of Regulatory Affairs
Business Wire - Thu Nov 13, 8:30AM CST
Carey Anderson has joined Biothera as Vice President of Regulatory Affairs for its Pharmaceutical business.
MACK: 8.39 (-0.16), AMGN: 160.24 (-1.69)
Merrimack Pharmaceuticals to Present Advances on Targeted Cancer Molecules at the 2014 AACR-NCI-EORTC International Conference
GlobeNewswire - Thu Nov 13, 7:02AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will present research on three of its therapeutic candidates at the 2014 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, November 18-21, 2014 in Barcelona, Spain. Data will be shared in four poster sessions. Presentations will include results from a clinical study using ferumoxytol as a magnetic resonance imaging agent and its ability to predict tumor response to MM-398, preclinical and clinical research on MM-151 and an initial preclinical study of MM-131, a novel bispecific antibody targeting the c-Met tumor signaling pathway.
MACK: 8.39 (-0.16)
Merrimack Pharma ups revenues 306% in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:09AM CST
MACK: 8.39 (-0.16)
Merrimack Pharmaceuticals' (MACK) CEO Bob Mulroy on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 9:29PM CST
MACK: 8.39 (-0.16)
Merrimack posts 3Q loss
Automated Insights - Mon Nov 10, 5:57PM CST
CAMBRIDGE, Mass. (AP) _ Merrimack Pharmaceuticals Inc. (MACK) on Monday reported a loss of $27.9 million, or 27 cents per share, in its third quarter.
MACK: 8.39 (-0.16)
Merrimack Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Mon Nov 10, 3:11PM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer, today announced its third quarter 2014 financial results. Merrimack will host a live conference call and webcast today, Monday, November 10 at 4:30 p.m., Eastern Time, to provide an update on Merrimack's progress as well as a summary of these results.
MACK: 8.39 (-0.16)
Merrimack Pharmaceuticals misses by $0.15, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:09PM CST
MACK: 8.39 (-0.16)
What To Watch For: November 10-14
TipRanks - Seeking Alpha - Mon Nov 10, 10:36AM CST
Quarterly report releases are winding down as we reach mid-November. Stay ahead of Wall Street with this week’s top stories: Monday, November 10 Sotheby’s (NYSE: BID ): a worldwide broker of fine art and real estate ...
BID: 40.84 (+0.07), DHI: 24.32 (+0.31), MGNX: 24.90 (+1.12), KSS: 56.08 (-1.83), HK: 3.04 (-0.01), SEAS: 17.03 (+0.18), DDD: 33.35 (-1.15), SBH: 30.40 (+1.03), WMT: 82.52 (+3.32), M: 61.37 (-0.20), HP: 77.67 (-7.89), NTAP: 40.95 (-1.36), ENR: 128.36 (+3.23), MACK: 8.39 (-0.16), W: 22.51 (+1.20), FOSL: 109.71 (-2.77), AMAT: 22.62 (+0.13), JCP: 7.14 (-0.62), JWN: 73.31 (+0.46), PE: 17.59 (-0.32), DF: 16.70 (-0.08), VIAB: 71.55 (+2.30), CSCO: 25.64 (+0.53), ATW: 34.31 (-1.21)
Will Inovio (INO) Disappoint Expectations for Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 3:35PM CST
Inovio (INO), which is scheduled to report third-quarter results on Nov 10, had delivered a negative earnings surprise of 11.76% in the last quarter.
MACK: 8.39 (-0.16), MNK: 86.81 (-6.18), INO: 10.92 (-0.18)
Can Merrimack (MACK) Keep the Earnings Streak Alive in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 3:30PM CST
Merrimack Pharmaceuticals, Inc. (MACK) has a Zacks Rank #2 and an Earnings ESP of +437.50%.
MACK: 8.39 (-0.16), MNK: 86.81 (-6.18), BAX: 72.09 (+0.76), LLY: 67.48 (+0.08)
Will Intercept Pharmaceuticals' (ICPT) Q3 Loss Narrow? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 3:02PM CST
Intercept Pharmaceuticals, Inc (ICPT) is slated to report its third-quarter 2014 results on Nov 7.
MACK: 8.39 (-0.16), MNK: 86.81 (-6.18), DNDN: 0.13 (-0.03), ICPT: 160.59 (-2.37)
Merrimack Pharmaceuticals Announces Initiation of Phase 1 Clinical Study of MM-398 for Brain Cancer
GlobeNewswire - Thu Nov 06, 7:42AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the first patient has been enrolled in a Phase 1 clinical study of MM-398 (nanoliposomal irinotecan injection) in a highly concentrated formulation in patients with recurrent high grade glioma, a type of aggressive brain tumor with poor prognosis. The study is being sponsored and conducted by Dr. Nicholas Butowski, M.D., Associate Professor of Neurological Surgery and Principal Investigator of the study at the University of California, San Francisco, and is supported by research grants from the National Institutes of Health and Merrimack.
MACK: 8.39 (-0.16), BAX: 72.09 (+0.76)
What's in Store for TrovaGene (TROV) This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 2:40PM CST
TrovaGene Inc. (TROV) is set to report third-quarter 2014 results on Nov 6.
MACK: 8.39 (-0.16), TROV: 4.54 (-0.28), PTCT: 40.88 (-0.44), HSIC: 130.04 (+0.36)
Merrimack cancer candidate tagged an Orphan Drug
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 10:26AM CST
MACK: 8.39 (-0.16)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 8:16AM CST
TTPH: 23.14 (-0.96), AWAY: 31.02 (+0.22), PHMD: 2.37 (-0.09), ROYT: 9.71 (-0.17), VG: 3.69 (-0.05), MEMP: 15.45 (-0.81), MACK: 8.39 (-0.16), ATVI: 20.18 (-0.23), NUS: 39.66 (-0.71), SSYS: 101.90 (-0.17), EOG: 94.86 (-2.70), CLNY: 24.63 (-0.05), CRTO: 38.02 (+0.74), IBIO: 1.12 (+0.01), NICE: 46.31 (-0.07), VPCO: 1.91 (+0.34), ZU: 28.55 (-0.06), EXEL: 1.78 (-0.03), ANV: 1.18 (+0.05), FEYE: 33.23 (+0.08), JIVE: 6.61 (-0.06), TRIP: 68.62 (-1.76), WLT: 2.76 (-0.30), YOD: 2.57 (-0.08), CHUY: 22.25 (-0.24), ANR: 2.38 (-0.24), NG: 2.78 (-0.02), AEZS: 0.60 (-0.01), ARIA: 6.28 (-0.19), CTSH: 53.21 (-0.03)
FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals' MM-141 for the Treatment of Pancreatic Cancer
GlobeNewswire - Wed Nov 05, 8:09AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to their investigational drug candidate MM-141 for the treatment of pancreatic cancer. MM-141 is a tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes containing IGF-1R and ErbB3 (HER3). The IGF-1R and HER3 complexes both activate a major cellular signaling pathway that allows tumor cells to grow and develop resistance to therapies.
MACK: 8.39 (-0.16)
Is a Surprise Coming for Merrimack Pharmaceuticals (MACK) This Earnings Season? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:36AM CST
Merrimack Pharmaceuticals has a favorable Zacks Rank and an ESP in positive territory, thus investors might want to consider this stock ahead of earnings.
MACK: 8.39 (-0.16)
Will Humana (HUM) Miss on Earnings Estimates this Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 2:50PM CST
Humana Inc. (HUM) is set to report third-quarter 2014 earnings results on Nov 7, 2014.
MACK: 8.39 (-0.16), MDVN: 106.83 (+0.50), ALNY: 99.90 (+0.05), HUM: 137.82 (+0.57)
Merrimack Pharma reports November 10
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 9:53AM CST
MACK: 8.39 (-0.16)
Prosensa Holding N.V. (RNA) Jumps: Stock Moves Up 9.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:39AM CST
Prosensa Holding N.V. (RNA) was a big mover last session, as its shares rose nearly 10% on the day.
MDVN: 106.83 (+0.50), MACK: 8.40 (-0.15), RNA: 11.47 (-0.28), ILMN: 184.41 (-2.51)
MACK Recent Posts: http://investorshangout.com/Merrimack-Pharmac...ACK-90045/
MACK Merrimack Pharmaceuticals Inc Recent Headline News
Biothera Names Carey Anderson VP of Regulatory Affairs
Business Wire - Thu Nov 13, 8:30AM CST
Carey Anderson has joined Biothera as Vice President of Regulatory Affairs for its Pharmaceutical business.
MACK: 8.39 (-0.16), AMGN: 160.24 (-1.69)
Merrimack Pharmaceuticals to Present Advances on Targeted Cancer Molecules at the 2014 AACR-NCI-EORTC International Conference
GlobeNewswire - Thu Nov 13, 7:02AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will present research on three of its therapeutic candidates at the 2014 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, November 18-21, 2014 in Barcelona, Spain. Data will be shared in four poster sessions. Presentations will include results from a clinical study using ferumoxytol as a magnetic resonance imaging agent and its ability to predict tumor response to MM-398, preclinical and clinical research on MM-151 and an initial preclinical study of MM-131, a novel bispecific antibody targeting the c-Met tumor signaling pathway.
MACK: 8.39 (-0.16)
Merrimack Pharma ups revenues 306% in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:09AM CST
MACK: 8.39 (-0.16)
Merrimack Pharmaceuticals' (MACK) CEO Bob Mulroy on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 9:29PM CST
MACK: 8.39 (-0.16)
Merrimack posts 3Q loss
Automated Insights - Mon Nov 10, 5:57PM CST
CAMBRIDGE, Mass. (AP) _ Merrimack Pharmaceuticals Inc. (MACK) on Monday reported a loss of $27.9 million, or 27 cents per share, in its third quarter.
MACK: 8.39 (-0.16)
Merrimack Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Mon Nov 10, 3:11PM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer, today announced its third quarter 2014 financial results. Merrimack will host a live conference call and webcast today, Monday, November 10 at 4:30 p.m., Eastern Time, to provide an update on Merrimack's progress as well as a summary of these results.
MACK: 8.39 (-0.16)
Merrimack Pharmaceuticals misses by $0.15, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:09PM CST
MACK: 8.39 (-0.16)
What To Watch For: November 10-14
TipRanks - Seeking Alpha - Mon Nov 10, 10:36AM CST
Quarterly report releases are winding down as we reach mid-November. Stay ahead of Wall Street with this week’s top stories: Monday, November 10 Sotheby’s (NYSE: BID ): a worldwide broker of fine art and real estate ...
BID: 40.84 (+0.07), DHI: 24.32 (+0.31), MGNX: 24.90 (+1.12), KSS: 56.08 (-1.83), HK: 3.04 (-0.01), SEAS: 17.03 (+0.18), DDD: 33.35 (-1.15), SBH: 30.40 (+1.03), WMT: 82.52 (+3.32), M: 61.37 (-0.20), HP: 77.67 (-7.89), NTAP: 40.95 (-1.36), ENR: 128.36 (+3.23), MACK: 8.39 (-0.16), W: 22.51 (+1.20), FOSL: 109.71 (-2.77), AMAT: 22.62 (+0.13), JCP: 7.14 (-0.62), JWN: 73.31 (+0.46), PE: 17.59 (-0.32), DF: 16.70 (-0.08), VIAB: 71.55 (+2.30), CSCO: 25.64 (+0.53), ATW: 34.31 (-1.21)
Will Inovio (INO) Disappoint Expectations for Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 3:35PM CST
Inovio (INO), which is scheduled to report third-quarter results on Nov 10, had delivered a negative earnings surprise of 11.76% in the last quarter.
MACK: 8.39 (-0.16), MNK: 86.81 (-6.18), INO: 10.92 (-0.18)
Can Merrimack (MACK) Keep the Earnings Streak Alive in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 3:30PM CST
Merrimack Pharmaceuticals, Inc. (MACK) has a Zacks Rank #2 and an Earnings ESP of +437.50%.
MACK: 8.39 (-0.16), MNK: 86.81 (-6.18), BAX: 72.09 (+0.76), LLY: 67.48 (+0.08)
Will Intercept Pharmaceuticals' (ICPT) Q3 Loss Narrow? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 3:02PM CST
Intercept Pharmaceuticals, Inc (ICPT) is slated to report its third-quarter 2014 results on Nov 7.
MACK: 8.39 (-0.16), MNK: 86.81 (-6.18), DNDN: 0.13 (-0.03), ICPT: 160.59 (-2.37)
Merrimack Pharmaceuticals Announces Initiation of Phase 1 Clinical Study of MM-398 for Brain Cancer
GlobeNewswire - Thu Nov 06, 7:42AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the first patient has been enrolled in a Phase 1 clinical study of MM-398 (nanoliposomal irinotecan injection) in a highly concentrated formulation in patients with recurrent high grade glioma, a type of aggressive brain tumor with poor prognosis. The study is being sponsored and conducted by Dr. Nicholas Butowski, M.D., Associate Professor of Neurological Surgery and Principal Investigator of the study at the University of California, San Francisco, and is supported by research grants from the National Institutes of Health and Merrimack.
MACK: 8.39 (-0.16), BAX: 72.09 (+0.76)
What's in Store for TrovaGene (TROV) This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 2:40PM CST
TrovaGene Inc. (TROV) is set to report third-quarter 2014 results on Nov 6.
MACK: 8.39 (-0.16), TROV: 4.54 (-0.28), PTCT: 40.88 (-0.44), HSIC: 130.04 (+0.36)
Merrimack cancer candidate tagged an Orphan Drug
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 10:26AM CST
MACK: 8.39 (-0.16)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 8:16AM CST
TTPH: 23.14 (-0.96), AWAY: 31.02 (+0.22), PHMD: 2.37 (-0.09), ROYT: 9.71 (-0.17), VG: 3.69 (-0.05), MEMP: 15.45 (-0.81), MACK: 8.39 (-0.16), ATVI: 20.18 (-0.23), NUS: 39.66 (-0.71), SSYS: 101.90 (-0.17), EOG: 94.86 (-2.70), CLNY: 24.63 (-0.05), CRTO: 38.02 (+0.74), IBIO: 1.12 (+0.01), NICE: 46.31 (-0.07), VPCO: 1.91 (+0.34), ZU: 28.55 (-0.06), EXEL: 1.78 (-0.03), ANV: 1.18 (+0.05), FEYE: 33.23 (+0.08), JIVE: 6.61 (-0.06), TRIP: 68.62 (-1.76), WLT: 2.76 (-0.30), YOD: 2.57 (-0.08), CHUY: 22.25 (-0.24), ANR: 2.38 (-0.24), NG: 2.78 (-0.02), AEZS: 0.60 (-0.01), ARIA: 6.28 (-0.19), CTSH: 53.21 (-0.03)
FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals' MM-141 for the Treatment of Pancreatic Cancer
GlobeNewswire - Wed Nov 05, 8:09AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to their investigational drug candidate MM-141 for the treatment of pancreatic cancer. MM-141 is a tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes containing IGF-1R and ErbB3 (HER3). The IGF-1R and HER3 complexes both activate a major cellular signaling pathway that allows tumor cells to grow and develop resistance to therapies.
MACK: 8.39 (-0.16)
Is a Surprise Coming for Merrimack Pharmaceuticals (MACK) This Earnings Season? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:36AM CST
Merrimack Pharmaceuticals has a favorable Zacks Rank and an ESP in positive territory, thus investors might want to consider this stock ahead of earnings.
MACK: 8.39 (-0.16)
Will Humana (HUM) Miss on Earnings Estimates this Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 2:50PM CST
Humana Inc. (HUM) is set to report third-quarter 2014 earnings results on Nov 7, 2014.
MACK: 8.39 (-0.16), MDVN: 106.83 (+0.50), ALNY: 99.90 (+0.05), HUM: 137.82 (+0.57)
Merrimack Pharma reports November 10
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 9:53AM CST
MACK: 8.39 (-0.16)
Prosensa Holding N.V. (RNA) Jumps: Stock Moves Up 9.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:39AM CST
Prosensa Holding N.V. (RNA) was a big mover last session, as its shares rose nearly 10% on the day.
MDVN: 106.83 (+0.50), MACK: 8.40 (-0.15), RNA: 11.47 (-0.28), ILMN: 184.41 (-2.51)
